12:46 PM EDT, 08/29/2025 (MT Newswires) -- GSK's (GSK) treatment of autosomal dominant polycystic kidney disease received orphan designation from the US Food and Drug Administration, the agency said Friday.

The designation is for a fully human monoclonal antibody that binds human pregnancy-related plasma protein A, the FDA said.

Price: 39.52, Change: +0.08, Percent Change: +0.19